Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include...
I went short yesterday after-hours at .95 at the 1.00 level. I set a Target order at .81. The target was hit today.
Easiest 2x I've seen in a very long time. Confidence level of gaining 100% in the near term is close to 100%. I wouldn't get too greedy holding long on this one. If you zoom out, it's eternal death. Get in and get out.
Some drugs address specific illnesses, while others enhance the pharmacokinetic responses of other drugs, which basically means that it assists other drugs. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)’s FHAB™ compound does both by causing swelling around tumors which assists in the immune response and catalyzes the effect of other treatments. As is, SONN...
everyones into this, these things just melt away, itll cetrainly go lower, but if it was to continue bouncing, here is your target, ggs
test Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded in 2011 and is headquartered in Princeton, New Jersey.
test Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded in 2011 and is headquartered in Princeton, New Jersey.
RSI @ all time frame lower all the time and additional volume expected soon. waiting for good news and performance. Good luck
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include...
1. Sonnet Bio Spikes 70% In Pre-Market On FDA Covid-19 Plasma Nod (FDA) has granted an emergency authorization to use blood plasma from recovered Covid-19 patients as a treatment for the disease. finance.yahoo.com 2. Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants as part of the previously announced warrant exchange agreement,...
Higher Price rejection after GAP up + Spike May try to fill the gap down yet again. If confirmed PT1 = 3,34 PT2 = 2,76 (For Gap Fill) Could see even lower
Higher Price rejection after GAP up + Spike May try to fill the gap down. If confirmed PT1 = 3,78 PT2 = 3,18 (For Gap Fill) Bonus PT3 = 2,59
SONN has bagged too many longs above $7's, thats why im expecting every bounce to $6's or above to get sold off, they just pulled the rug from $6.4 now down to 5.6 strong Resis at 6-6.25 dollar area
All, This one could explode tomorrow or soon. Definitely a pump and dump nothing more. Just wait and see.
Could be a hot stock among day traders today